According to the latest report published by Acute Market Reports, Inc., the global market for post-traumatic stress disorder therapeutics is projected to reach US$ 10,679.5 million by 2026, increasing to CAGR by 4.5 per cent from 2018 to 2026.
Post-traumatic stress disorder (PTSD) therapeutics market projected to an extent by US$ 10,679.5 Mn by 2026 with a CAGR of 4.5% throughout the forecast period from 2018 to 2026. Antidepressants are the class of promising drugs that play a stellar role in the market. Global post-traumatic stress disorder therapeutics market from 2018 to 2026 has been prepared based on exhaustive analysis with insights from industry professionals. The detailed study incorporates the market landscape and its growth scenarios for the forecast period from 2018 to 2026. To estimate the market size, the report ruminates branded, generic and pipeline drugs.
Browse Full Report Originally Published by Acute Market Reports at https://www.acutemarketreports.com/report/post-traumatic-stress-disorder-therapeutics-market
As per the U.S. National Comorbidity Survey Replication, around 6.8% individuals experience the ill effects of PTSD. As indicated by PTSD United, Inc. around 70% of individuals in the United States has encountered a few sorts of the shocking accident in any event once in their lives. This associate to around 223.4 million individuals. The usage rate of healthcare services is highest in case of individuals suffering from PTSD. There are various symptoms that are commonly grouped into four different types: avoidance, changes in physical and emotional reactions, negative changes in thinking and mood, and intrusive memories that are identified in the individuals having post-traumatic stress disorder.
Based on the class of drug, the global post-traumatic stress disorder therapeutics market is segmented into antidepressants, anti-anxiety drugs, other drug classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants), and pipeline candidates. Rising prevalence of PTSD and the promising drug pipeline would additionally boost the post-traumatic stress disorder therapeutics market.
Geographically, the overall post-traumatic stress disorder therapeutics market is projected for the Middle East and Africa, Europe, North America, Latin America, and the Asia Pacific. North America currently drives the global market and projected to hold its supremacy throughout the forecast period. However, Europe will be clearly challenged by the Asia Pacific by end of the forecast period. The need for post-traumatic stress disorder therapeutics drugs has become prominent in the Asia Pacific because of rapidly increasing events such as sexual assault, combats and inter-personal violence. There are massive chances for market penetration in countries like China, and India by the market leaders who at present have a stronghold in developed countries.
You can get the sample copy of this research by Acute Market Reports here: https://www.acutemarketreports.com/request-free-sample/137571
Report Scope by Segments
Drug Class Segment
- MAO Inhibitors
- Tricyclic Antidepressants
By Anti-anxiety Drugs
By Other Drug Class
- Alpha-1 & Alpha-2 Receptor Antagonists
- Atypical Antipsychotics
By Pipeline Candidates (Qualitative information)
- SRX 246 (Phase II)
- BNC 210 (Phase II)
- Tonmya (Phase II)
By Geography Segment
• North America (U.S., Rest of North America)
• Europe (U.K., Germany, France, Rest of Europe)
• Asia Pacific (China, Japan, India,Rest of Asia Pacific)
• Rest of the World (Middle East & Africa, Latin America)